WallStSmart

Boston Scientific Corp (BSX)vsConocoPhillips (COP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ConocoPhillips generates 200% more annual revenue ($60.28B vs $20.07B). BSX leads profitability with a 14.4% profit margin vs 13.3%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

COP

Hold

48

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued
COPSignificantly Overvalued (-157.1%)

Margin of Safety

-157.1%

Fair Value

$43.25

Current Price

$128.93

$85.68 premium

UndervaluedFair: $43.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

COP3 strengths · Avg: 8.3/10
Market CapQuality
$157.60B9/10

Large-cap with strong market position

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

COP3 concerns · Avg: 2.0/10
PEG RatioValuation
4.222/10

Expensive relative to growth rate

Revenue GrowthGrowth
-6.8%2/10

Revenue declined 6.8%

EPS GrowthGrowth
-39.0%2/10

Earnings declined 39.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : COP

The strongest argument for COP centers on Market Cap, Price/Book, Free Cash Flow.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : COP

The primary concerns for COP are PEG Ratio, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

BSX profiles as a growth stock while COP is a declining play — different risk/reward profiles.

BSX carries more volatility with a beta of 0.70 — expect wider price swings.

BSX is growing revenue faster at 15.9% — sustainability is the question.

COP generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 48/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

ConocoPhillips

ENERGY · OIL & GAS E&P · USA

ConocoPhillips is an American multinational corporation engaged in hydrocarbon exploration. It is based in the Energy Corridor district of Houston, Texas.

Want to dig deeper into these stocks?